Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors: Phase II, Multicenter, Randomized, Controlled Clinical Trial

NCT02283489 is registered in ClinicalTrials.gov with Renmiao Zhang as lead sponsor.

NCT NCT02283489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors: Phase II, Multicenter, Randomized, Controlled Clinical Trial
Lead sponsor
Renmiao Zhang
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2014
Completion date
October 31, 2016
Enrollment
180 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms